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Abstract 
Introduction: A meningeal haemangiopericytoma (HP) is a mesenchymal tumour that 
makes up less than 1% of all CNS tumours. HPs arise from pericytes and present high 
rates of recurrence and distant metastasis. The primary treatment option is surgery. 
When the disease is disseminated, chemotherapy produces a weak and short-lived 
response; therefore, new drugs are needed.  
Case Presentation: We describe the case of a 65-year-old woman with a 13-year history 
of recurrent HP. After local treatment with radiotherapy, she developed metastases that 
required systemic treatment, and treatment with sunitinib, an oral inhibitor of the 
vascular endothelial growth factor receptor and the platelet-derived growth factor 
receptor, was initiated. As a result, radiological stabilisation of the systemic disease was 
maintained for over 12 months.  
Conclusions: Anti-angiogenic agents can be useful for treating disseminated HP, but 
further studies are needed to confirm their possible role in controlling metastatic 
disease. 
Introduction 
A meningeal haemangiopericytoma (HP) is a rare mesenchymal tumour that arises 
from the cells surrounding the capillary wall. Its aetiology is unknown, and 25% of cases 
occur in the head or neck. Meningeal HP makes up less than 1% of all CNS tumours; it is 
very aggressive and presents high rates of local recurrence and distant metastasis, most  
Case Rep Oncol 2011;4:55–59 
DOI: 10.1159/000324487 
Published online: 
February 5, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
56
frequently in the lungs and the bones. Surgery is the normal treatment, and no clear role 
has been established for either radiotherapy or chemotherapy. 
The hypothesis that this type of tumour could be sensitive to angiogenesis inhibitors is 
based on the fact that these tumours are highly vascularised and express platelet-derived 
growth factor receptor (PDGFR) and vascular endothelial growth factor receptor 
(VEGFR). However, few cases of patients treated with anti-angiogenic drugs have been 
reported. The low prevalence of this tumour prevents the implementation of clinical trials 
that could confirm our hypothesis. 
Case Presentation 
A 65-year-old woman with a personal history of arterial hypertension who had been treated for 
parotid adenoma came to our clinic in November 1997. She was diagnosed with a 30-mm meningeal 
tumour in the sellar cavity. A biopsy was performed, and the anatomopathological results were 
compatible with meningeal HP. Resectioning of the tumour was decided against in view of the likely 
outcome, and so the patient was given 17 Gy of stereotactic radiotherapy in one fraction. Complete 
radiological remission was achieved. At 39 and at 65 months, local relapses occurred, and stereotactic 
radiotherapy was administered. 
In January 2009, the patient complained of pain, which had developed over months, in the right 
upper arm. Radiography was performed and revealed a 70-mm permeative lesion in the middle third of 
the right humerus. MRI of this area showed the lesion to be of a lytic nature, with an intermediate signal 
in T1 and T2 and perilesional oedema. An extension study was performed, involving a helical 
computerised axial tomography (CAT) scan, which revealed a nodular image measuring 22 mm in the 
paraspinal muscles between the 11th and 12th ribs and two hepatic lesions in segments 3 and 7, 
measuring 24 and 22 mm, respectively. A humeral biopsy was then performed, and the 
anatomopathological results revealed the existence of HP. 
With clinical evidence of HP metastatic relapse in the bone, soft tissues and liver, we decided to 
apply radiotherapy to the lesions in the humerus and the lower left dorsal paraspinal muscles due to the 
pain experienced in those regions and to obtain evolutive control of the hepatic lesions. 
After 4 months of monitoring, a CAT re-evaluation was performed, and the diameter of the 
irradiated paravertebral lesion had decreased by 50%, while the hepatic lesions had enlarged to 38 and 
25 mm, respectively (fig. 1). The cranial CAT revealed a hyperechoic mass measuring 20 mm with a 
meningeal base at the apex of the petrous bone; it could not be discerned whether this corresponded to 
residual remains or to a tumoural relapse. 
In June 2009, progression to the liver suggested the need to begin treatment with 37.5 mg sunitinib 
daily. Initially, the patient suffered increased abdominal pain and jaundice. After 1 month of treatment 
with anti-VEGFR, analysis revealed a two-fold increase in the values of GOT, GPT and GGT to 80, 83 
and 81 U/l, respectively, while AP levels rose to 169 U/l and LDH to 567 U/l. Abdominal echography 
was performed, and the two hepatic lesions in segments 3 and 7 were observed to measure 30 and 70 
mm, respectively. One of the lesions, thus, was smaller while the other was larger than at the time of the 
previous CAT scan. We assumed that ischemia of the lesions might have been induced by the 
administration of sunitinib, and so the treatment was continued. 
In the control echography carried out after 1 month, the same lesions were observed, measuring 30 
and 55 mm, respectively. They were more hypoechoic than they had been previously. The patient 
showed an acceptable degree of tolerance, although with grade II thrombocytopenia and grade III 
neutropenia, with episodes of epistaxis and petechiae on the lower eyelids, it was necessary to reduce the 
dose of sunitinib to 25 mg daily for 4 weeks, followed by 2 weeks of rest. 
The image tests carried out from the start of anti-VEGFR treatment in June 2009 until September 
2010 revealed disease stabilisation (fig. 2) in the liver and head. The patient therefore continued the 
same treatment, and no significant level of toxicity was observed.  
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Discussion 
Meningeal HP is a very rare tumour, but it is aggressive, with a tendency to recur and 
to metastasise. In studies by Mena et al. [1] of 94 patients and Guthrie et al. [2] of 44 
patients with HP, recurrences were reported in 60.6 and 65% of the cases, and metastases 
were reported in 23.4 and 33% of the patients, respectively. 
The normal treatment for meningeal HP is surgical resection. In some clinics, adjuvant 
radiotherapy is applied, although the retrospective study by Dufour et al. [3] did not find 
any reduction in the rate of metastasis with adjuvant radiotherapy. 
The utility of chemotherapy is unclear; various chemotherapeutic agents have been 
used in the treatment of metastasic HP, but no consensus has been reached as to the most 
appropriate drug, dose, form of administration, scheme or response criteria, and so the 
results obtained should be interpreted with caution. Adriamycin, alone or in 
combination, appears to be the most effective agent, with 6/12 (50%) complete or partial 
responses and 4/12 (33%) minor responses. Other drugs, such as cyclophosphamide, 
vincristine, methotrexate, actinomycin and DTIC, may exert some anti-tumoural activity, 
but due to the small number of patients under such treatment and because these drugs are 
often used in combinations, it is not possible to establish a protocol for application based 
on the results of previous studies [4, 5]. 
The immunohistochemical expression of VEGFR has been described in the tumoural 
cells of HP and in the endothelium, with overexpression of VEGFR1 and VEGFR2 only in 
the endothelium, suggesting that the autocrine and paracrine activation of the VEGF–
VEGFR pathway may participate in the biology of HP [6]. A study by Dietzmann et al. [7] 
showed that angiomatous meningiomas and HPs frequently overexpress PDGFR and that 
this overexpression is detectable by immunohistochemistry. 
Sunitinib is a tyrosine kinase inhibitor of VEGFR, PDGFR and fibroblast growth 
factor, with antiproliferative and anti-angiogenic properties. Among the anti-angiogenic 
treatments used for HP, interferon-α and/or thalidomide [8] have been shown to induce 
partial responses and disease stability. Other patients have been treated with tyrosine 
kinase inhibitors such as sunitinib [9, 10], sorafenib [10] or dasatinib [11] as first-line or 
successive treatments. In some of these patients, disease stabilisation lasting over 6 
months has been achieved; others have enjoyed clinical benefits or even durable partial 
response (table 1). 
Conclusions 
Because HP is a tumour with a high probability of distant metastasis that shows little 
and short-lived response to chemotherapy, new drugs are needed to tackle disseminated 
disease. Anti-angiogenic treatment, for example, utilising anti-VEGFR drugs, could play a 
role in these new treatment regimens, but trials are needed to test this hypothesis because, 
to date, only individual cases have been reported.  
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Table 1. Overview of previous studies of anti-angiogenic treatment 
Study Anti-angiogenic 
treatment 
Previous systemic treatments  Response to anti-
angiogenic treatment 
Delgado et al.  sunitinib (1 case)  no  DS after >15 months 
Kirn and Kramer [8]  IFN-α (2 cases)  no 
no 
PR after 16 months 
DS after 24 months 
Mulamalla et al. [9]  sunitinib (1 case)  no  DS after >10 months 
Domont et al. [10]  sorafenib (1 case) 
 
sunitinib (1 case) 
cisplatin, epirubicin, I-phosphamide, 
trabectedin, paclitaxel, dacarbazine 
anthracyclines 
DS after 15 months 
 
DS after 6 months 
(suspended due to 
toxicity) 
Peters et al. [11]  dasatinib (1 case)  octreotide and (90)Y-dodecane-
tetraacetic acid Phel-Tyr3-octreotide 
DS after >24 months 
DS = Disease stabilisation; IFN = interferon; PR = partial response. 
 
 
 
 
 
Fig. 1. Metastatic hepatic lesion in segment 3 measuring 38 mm before treatment with sunitinib. April 
2009. 
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Fig. 2. Metastatic hepatic lesion in segment 3 measuring 30 mm after treatment with sunitinib. May 
2010. 
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